EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Changes in dystrophic calcification of the breast associated with abaloparatide therapy

Azucena Micaela Herrera Chancay iD, Anupriya Bhatnagar, Soume D Foshee, Mariam Mir, Kyaw K Soe iD

JCEM Case Reports · 16.10.2026 · 4 (12)

DOI: 10.1210/jcemcr/luag340 ↗

Kurz gefasst

Fallbericht in der Zeitschrift JCEM Case Reports, online erschienen am 17.11.2026. Verfasst von Azucena Micaela Herrera Chancay und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Veterans Affairs North Texas Healthcare System, Dallas, TX 75216, USA. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

High-risk osteoporosis treatment strategy aims at improving bone mineral density and fracture prevention. Clinicians' awareness of the indications and potential complications associated with osteoporosis treatments is important because it involves caring for patients with comorbidities who experience polypharmacy. We present a case of breast calcification changes after initiation of abaloparatide. A 65-year-old female started abaloparatide therapy and after 8 months of abaloparatide treatment, a significant progression of bilateral breast calcification was noted in screening mammogram prompting a biopsy that showed coarse calcifications without any features of dysplasia or malignancy. After 2 years of abaloparatide therapy, follow-up mammogram revealed stable breast calcifications but that were still significantly increased from baseline prior to abaloparatide. In the absence of possible etiologies such as trauma, end-stage renal disease, or secondary hyperparathyroidism, the strong temporal association suggested abaloparatide treatment as the possible etiology for changes of benign breast calcification.

Schlagwörter

Stichwörter der Autor:innen

abaloparatidebreast calcificationosteoporosis

Autor:innen und Institutionen

  • Department of Medicine, Veterans Affairs North Texas Healthcare System, Dallas, TX 75216, USA.
  • Division of Endocrinology and Metabolism, Department of Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.

ORCID-Profile: Azucena Micaela Herrera Chancay, Kyaw K Soe

Zitieren

APA

Herrera Chancay, A. M., Bhatnagar, A., Foshee, S. D., Mir, M., & Soe, K. K. (2026). Changes in dystrophic calcification of the breast associated with abaloparatide therapy. JCEM Case Reports, 4(12). https://doi.org/10.1210/jcemcr/luag340

Vancouver

Herrera Chancay AM, Bhatnagar A, Foshee SD, Mir M, Soe KK. Changes in dystrophic calcification of the breast associated with abaloparatide therapy. JCEM Case Reports. 2026;4(12). doi:10.1210/jcemcr/luag340

BibTeX
@article{HerreraChancay2026,
  author = {Herrera Chancay, Azucena Micaela and Bhatnagar, Anupriya and Foshee, Soume D and Mir, Mariam and Soe, Kyaw K},
  title = {Changes in dystrophic calcification of the breast associated with abaloparatide therapy},
  journal = {JCEM Case Reports},
  year = {2026},
  volume = {4},
  number = {12},
  doi = {10.1210/jcemcr/luag340}
}
Kostenlos starten →